

Letter to the Editor

# CAR-T Cells: An Innovative Therapeutic Strategy Against Pediatric Acute Lymphoblastic Leukemia

Mohsen Sheykhasan<sup>1,2</sup>, Hamed Manoochehri<sup>1</sup>, Leila Naserpour<sup>3</sup>, and Naser Kalhor<sup>2</sup>

<sup>1</sup>Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

<sup>2</sup>Department of Mesenchymal Stem Cell, The Academic Center for Education, Culture and Research, Qom Branch, Qom, Iran

<sup>3</sup>Department of Reproductive Biology, The Academic Center for Education, Culture and Research, Qom Branch, Qom, Iran

**Keywords:** CART cells, pediatric

Corresponding Author:

Naser Kalhor;

Department of Mesenchymal Stem Cell, The Academic Center for Education, Culture and Research, Qom Branch, Qom, Iran

email: kalhor@acecr.ac.ir

naserkalhor@gmail.com

Tel/fax: + 98-25-32700155

Production and Hosting by Knowledge E

© Mohsen Sheykhasan

et al. This article is distributed under the terms of the

Creative Commons

Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Editor-in-Chief:

Dr. Alireza Rafiei

## Dear editor

Acute lymphoblastic leukemia (ALL) is a prevalent and highly progressive cancer in children and adolescents associated with an excessive production of immature lymphocytes in the bone marrow, which causes a negative effect on the production of other blood components, such as red blood cells, platelets, and other white blood cells (1-3).

The survival rate of ALL was only 10% in children in the 1960s, but reached 90% by 2015; however, the survival rate remains 80–90% among very young children (2, 4-6).


Chemotherapy is the primary treatment for ALL, along with auxiliary therapies to ameliorate its severe side effects; however, hematopoietic stem cell transplantation and immunotherapy are two emerging and promising approaches for the treatment of ALL (6-9).

Immunotherapy for pediatric ALL involves the use of genetically modified T cells, called chimeric antigen receptor (CAR)-T cells, which are autologous or allogeneic immune T cells that have been produced to identify and eliminate cancer cells more specifically by targeting one or several cancer-related proteins, notably, CD19 and CD22, or both (Figure 1) (6, 10).

According to the data presented by clinicaltrials.gov, until 2018, twelve clinical studies have been performed on pediatric leukemia, especially ALL, involving the use of CAR-T cells on ~394 patients. However, these were all early-stage trials (Phase I or Phase I/II) (6).

Of these twelve studies, ten involved CD19-targeted CAR-T cells, while four involved CD22-targeted CAR-T cells (6).

 OPEN ACCESS



**Figure 1:** CAR-T Cells in the treatment of B-cell malignancies. BCR indicates B-cell receptor; CAR, chimeric antigen receptor; CCR4, CC chemokine receptor 4. CAR-modified T cells targeting the transmembrane proteins CD19 and CD22 on a malignant B cell. T-cell activation leads to the apoptosis of the cancer cell (22).

Furthermore, in a Phase I clinical trial, it was demonstrated that a bicistronic CAR-T cell therapy called AUTO3 served as a promising therapy for pediatric patients with relapsed/refractory (R/R) B-cell ALL, by simultaneously targeting CD19 and CD22 (11). Similarly, a Phase I clinical trial study has indicated the efficiency and safety of bispecific CAR-T cells, which simultaneously target CD19 and CD22, in pediatric ALL patients (12).

These data, along with those from previous studies, demonstrate the potential of CAR T-cells for treating leukemia, especially ALL (6, 13, 14).

In addition, tisagenlecleucel (Kymriah<sup>TM</sup>), an autologous CD19-targeted CAR-T cell immunotherapy, has been recently introduced as a Food and Drug Administration- and European Union-approved cell-based therapy for use in pediatric patients with relapsed/refractory (R/R) B-cell precursor ALL (15-18).

According to previous studies, 83% of patients have demonstrated a partial or complete response to treatment following a single injection of tisagenlecleucel over a short period (19). Besides the high response rate to treatment, the time period after primary treatment without certain complications or adverse events in pediatric ALL patients was longer, and their overall survival was higher following tisagenlecleucel-based treatments than other cancer treatments (20).

However, the long-term efficiency and safety of this approach remains unclear and challenging (21). Additionally, thus far, cytokine release syndrome, neurological toxicity, and other toxicities have been recognized as the most commonly known complications of this method (22). Furthermore, cardiovascular and neurodegenerative disorders can be attributed to the toxic effects of CAR-T cells (23).

Hence, this modern treatment should be employed along with specialized medical care by medical groups with diverse expertise and the required facilities to certify optimal patient consequences (23).

Additionally, the cost of this treatment is very high, at €282,000 per patient (24).

Thus, CAR T-cells could aid the treatment of ALL patients and reverse the process of disease by identifying and killing cancer cells (6).

Clinical studies have demonstrated the potential of CAR-T cells to serve as a successful treatment strategy for pediatric ALL when chemotherapy has failed.

## Acknowledgements

We express our deepest gratitude to Mrs. Farzaneh Chitsaz for her help with manuscript writing.

## Conflicts of Interest

The authors declare no conflicts of interest.

## References

- [1] Li Y, Zhu R, Mi L, Cao Y, Yao D. Segmentation of white blood cell from acute lymphoblastic leukemia images using dual-threshold method. *Comput Math Methods Med*. 2016;2016:1-12.
- [2] Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. *Leukemia*. 2018; 32(11):2316-2325.
- [3] Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. *Pediatr Int*. 2018;60(1):4-12.
- [4] Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *J Clin Oncol*. 2012;30(14):1663-1669.
- [5] Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. *N Engl J Med*. 2015;373(16):1541-52.
- [6] Pehlivan KC, Duncan BB, Lee DW. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. *Curr Hematol Malig Rep*. 2018; 13(5):396-406.
- [7] Jayachandran D, Rundell AE, Hannemann RE, Vik TA, Ramkrishna D. Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment. *PloS one*. 2014;9(10):e109623.
- [8] Ness KK, Armenian SH, Kadan-Lottick N, Gurney JG. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. *Expert Rev Hematol*. 2011;4(2):185-97.
- [9] Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT. Tisagenlecleucel for the treatment of B cell acute lymphoblastic leukemia. *Expert Rev Anticancer Ther*. 2018; 18(10):959-971.
- [10] Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. *Nat Med*. 2018;24(1):20-28.
- [11] Amrolia PJ, Wynn R, Hough R, Vora A, Bonney D, Veys P, et al. Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in

- Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study. *Am Soc Hematology*; 2018; 132(1 Suppl):279-279.
- [12] Schultz LM, Davis KL, Baggott C, Chaudry C, Marcy AC, Mavroukakis S, et al. Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). *Am Soc Hematology*; 2018; 132(1 Suppl):898-898.
- [13] Das RK, Storm J, Barrett DM. T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential. *AACR*; 2018; 78(13 Suppl):1-1.
- [14] Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. *Am Soc Hematology*; 2018; 132(Suppl 1):895-895.
- [15] Prasad V. Immunotherapy: Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. *Nat Rev Clin Oncol*. 2018;15(1):11-12.
- [16] Yu TTL, Gupta P, Ronfard V, Vertès AA, Bayon Y. Recent progress in European advanced therapy medicinal products and beyond. *Front Bioeng Biotechnol*. 2018;6:130.
- [17] Boyer MW. Chimeric antigen receptor T-cell therapy hits the market. *Immunotherapy*. 2018; 10(11):911-912.
- [18] och DLBCL OA. EU-kommissionen godkänner Novartis' CAR-T-cellbehandling Kymriah (tisagenlecleucel) [available from: <https://www.ascopost.com/issues/august-10-2018/car-t-cell-therapy-in-lymphoma/>].
- [19] Helwick C. CAR T-Cell Therapy in Lymphoma: Challenges Come With Success [available from: <https://www.england.nhs.uk/2018/11/first-children-with-cancer-to-begin-treatment-with-revolutionary-car-t-therapy/>].
- [20] Zheng P-P, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. *Drug Discov Today*. 2018; 23(6):1175-1182.
- [21] Whittington MD, McQueen R, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor t-cell therapy for pediatric patients with relapsed or refractory leukemia. *JAMA Pediatr*. 2018; 172(12):1161-1168.
- [22] Thomas X, Paubelle E. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia. Expert opinion on biological therapy. *Expert Opin Biol Ther*. 2018; 18(11):1095-1106.
- [23] Mahadeo K, Khazal S, Abdel-Azim H, Fitzgerald J, Taraseviciute A, Bollard C, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. *Nat Rev Clin Oncol*. 2018; 16(1):45-63.
- [24] England SS. NHS England to fund CAR-T for childhood leukaemia. *PharmacoEconomics & Outcomes News*. 2018;812:37-22. available from: <https://www.england.nhs.uk/2018/11/first-children-with-cancer-to-begin-treatment-with-revolutionary-car-t-therapy/>